Industry Outlook

Across the world, deep brain stimulation (DBS) is being used for treating pain and movement disorders such as tremors and Parkinson’s disease. Some other recognized conditions for deep brain stimulation include epilepsy, obsessive compulsive disorders and dystonia. There are other conditions such as Tourette syndrome, bipolar disorder, auditory disorders, tinnitus and others, which are investigational for DBS therapy. Particularly about DBS for psychiatric disorders, the subcommittee of the World Society for Stereotactic and Functional Neurosurgery had published consensus on Guidelines for Stereotactic Neurosurgery for Psychiatric Disorders. This suggested that DBS for psychiatric disorders is investigational and the procedures need to be done based on scientific protocol, by multidisciplinary team and with regulatory and ethical oversight. Over a million patients have been treated with DBS worldwide and the potential patient population is still growing. Furthermore, as there is no inaccessible area in the brain, the limit as to where the electrodes can be applied is nonexistent. Therefore, there is no limit to the diseases treatable with DBS. This in turn, has raised certain ethical issues, particularly with respect to neuroethics concerning alteration of central nervous system circuitry. Hence, the ethical front of the application of DBS should be determined on the basis of the current social philosophy.

"Subthalamic Nucleus to Remain the Commonly Used Target for DBS"

DBS of the brain thalamus was first approved by the USFDA for tremors in 1997. Afterwards, DBS for subthalamic nucleus (STN) and globus pallidus interna (GPi) for Parkinson’s disease were approved in 2002 and 2003 respectively. The GPi DBS gained further approval for dystonia treatment under humanitarian device exemption in 2003. At present GPi and STN are the prominent viable targets for DBS. The choice of site mainly focuses on the type of motor and non-motor symptoms, being the key determinants of quality of life. The STN is the most commonly used target for DBS for the treatment of Parkinson’s disease. The STN is a prime location in the basal ganglia circuits therefore serve as a major target for cortical afferents and receive inputs from other parts of the basal ganglia. About half of the DBS treatments for Parkinson’s disease are performed on the STN target. STN DBS offers very effective therapy for certain motor symptoms of Parkinson’s disease such as stiffness, tremors and bradykinesia, therefore gaining high popularity in the market. on the other hand, dystonia patients often opt for GPi DBS, as it offers significant remission of painful cramping and posturing. GPi DNS is also effective for relieving motor symptoms of Parkinson’s disease.

"Proven Benefits and Efficacy of DBS in Parkinson’s Disease to Remain the Mainstay for Market Growth"

Following the success of DBS in treating Parkinson’s disease, DBS surgery has revamped the interest in neurological management of psychiatric disorders. Based on this DBS received FDA approval for treatment of obsessive compulsive disorder on humanitarian device exemption status. Other conditions in which DBS therapy is shown to have benefits include epilepsy, neuropathic pain, post-stroke pain, depression, cluster headache, multiple sclerosis tremors and so on. DBS surgery is also being investigated for addictions, traumatic brain injury, eating disorders, and post-traumatic stress disorders. At present DBS application for Parkinson’s disease treatment dominates the global market. Proven clinical evidence and early bird advantage are the key factors assisting the prominence of DBS for Parkinson’s disease segment. DBS has gradually become the procedure of choice for Parkinson’s disease treatment as it does not involve destruction of the brain tissue, adjustable and can be reversed. GPi and STN are the preferred targets for DBS for Parkinson’s disease. However, reports suggest that Vim can also be used in cases of primary symptoms of tremors.

"North America to Dominate the Global Market through the Forecast Period due to Significantly Large Patient Pool"

Currently, North America leads the global deep brain stimulation devices market. Greater prevalence of neurological conditions, faster diagnosis and adoption rates, and better reimbursements mainly contribute to the dominance of North America market. Europe is estimated to be the second in lead on the global front. Intensive marketing of DBS and rapid adoption of novel technologies in the region facilitates the prime position of North America. Additionally, Asia Pacific will advance at the fastest growth rate during the forecast period. Improving government policies for attracting players from the developed regions, evolving reimbursements, growing awareness and skills, and proliferating medical tourism industry in the region facilitate the progress of Asia Pacific market.

The report also includes competitive analysis of the prominent players in the global deep brain stimulation devices market. The profiles of such players are also assessed in the study based on their business overview, product portfolio, financial information, and key developments. The prime players operating in the global deep brain stimulation devices market are Medtronic Plc, Boston Scientific Corporation, Abbott (St. Jude Medical, Inc.), Aleva Neurotherapeutics SA, NeuroPace, Inc., PINS Medical Co., Ltd.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Deep Brain Stimulation Devices market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Deep Brain Stimulation Devices market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Deep Brain Stimulation Devices market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Deep Brain Stimulation Devices market?
• Which is the largest regional market for Deep Brain Stimulation Devices market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Deep Brain Stimulation Devices market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Deep Brain Stimulation Devices market worldwide?